公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2023 | Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 | Satake, Hironaga; Lee, Keun-Wook; Chung, Hyun Cheol; Lee, Jeeyun; Yamaguchi, Kensei; Chen, Jen-Shi; Yoshikawa, Takaki; Amagai, Kenji; KUN-HUEI YEH ; Goto, Masahiro; Chao, Yee; Lam, Ka-On; Han, Shi Rong; Shiratori, Shinichi; Shah, Sukrut; Shitara, Kohei | Japanese journal of clinical oncology | 1 | 0 | |
2023 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | Rha, Sun Young; Oh, Do-Youn; Yañez, Patricio; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernández, Manuel González; Li, Jin; Lowery, Maeve A; Çil, Timuçin; Cruz, Felipe Melo; Qin, Shukui; Luo, Suxia; Pan, Hongming; Wainberg, Zev A; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Wyrwicz, Lucjan S; KUN-HUEI YEH | The Lancet. Oncology | 21 | | |
2018 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial | Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH ; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators | The Lancet | 946 | 844 | |
2011 | Personality trait and quality of life in colorectal cancer survivors | Shun S.-C.; FEI-HSIU HSIAO ; YEUR-HUR LAI ; JIN-TUNG LIANG ; KUN-HUEI YEH ; JOHN HUANG | Oncology Nursing Forum | 16 | 15 | |
2016 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | SHIH-HUNG YANG ; TING-CHUN KUO ; Wu H.; JHE-CYUAN GUO ; CHIUN HSU ; CHIH-HUNG HSU ; YU-WEN TIEN ; KUN-HUEI YEH ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastroenterology | 24 | 25 | |
2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. | Gastric Cancer | 140 | 130 | |
2015 | Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients | Chang T.C.; Shiah H.S.; CHIH-HSIN YANG ; KUN-HUEI YEH ; ANN-LII CHENG ; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T. | Cancer Chemotherapy and Pharmacology | 87 | 74 | |
2018 | A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma | SHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 3 | 2 | |
2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 63 | 64 | |
2011 | Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers | Ho Y.-F.; Lu W.-C.; Chen R.R.-L.; ANN-LII CHENG ; KUN-HUEI YEH | Anti-Cancer Drugs | 5 | 3 | |
2011 | A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan | Chen J.-S.; Chao Y.; Hsieh R.-K.; ANN-LII CHENG ; Chen P.-M.; Chiou T.-J.; Chao T.-Y.; KUN-HUEI YEH ; Chen L.-T.; Whang-Peng J. | Cancer Chemotherapy and Pharmacology | 6 | 5 | |
2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
2018 | Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma | Javle M.; Lowery M.; Shroff R.T.; Weiss K.H.; Springfeld C.; Borad M.J.; Ramanathan R.K.; Goyal L.; Sadeghi S.; Macarulla T.; El-Khoueiry A.; Kelley R.K.; Borbath I.; Choo S.P.; Oh D.-Y.; Philip P.A.; Chen L.-T.; Reungwetwattana T.; Van Cutsem E.; KUN-HUEI YEH ; Ciombor K.; Finn R.S.; Patel A.; Sen S.; Porter D.; Isaacs R.; Zhu A.X.; Abou-Alfa G.K.; Bekaii-Saab T. | Journal of Clinical Oncology | 513 | 428 | |
2004 | Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | Lu Y.-S.; CHIUN HSU ; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIH-HUNG HSU ; Wu C.-Y.; ANN-LII CHENG | Hepato-Gastroenterology | 14 | 13 | |
2019 | Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma | Ta-Chen Huang ; CHIA-CHI LIN ; Wu Y.-C.; CHIA-HSIEN CHENG ; JANG-MING LEE ; HSIU-PO WANG ; PEI-MING HUANG ; Feng-Ming Hsu ; KUN-HUEI YEH ; ANN-LII CHENG ; KAI-YUAN TZEN ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 8 | 6 | |
1997 | A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers | KUN-HUEI YEH ; ANN-LII CHENG ; Lin M.-T.; RUEY-LONG HONG ; CHIH-HUNG HSU ; Lin J.-F.; KING-JEN CHANG ; PO-HUANG LEE ; YAO-CHANG CHEN | Anticancer Research | 32 | 27 | |
2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
2004 | Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer | Chao Y.; KUN-HUEI YEH ; Chang C.J.; Chen L.T.; Chao T.Y.; Wu M.F.; Chang C.S.; Chang J.Y.; Chung C.Y.; Kao W.Y.; Hsieh R.K.; ANN-LII CHENG | British Journal of Cancer | 72 | 63 | |
2005 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.-F.; CHIUN HSU ; SUNG-HSIN KUO ; Li Jr. S.; ANN-LII CHENG | Oncology | 22 | 22 | |
2005 | Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.F.; Chao H.J.; Ta-Chen Huang ; Chung C.Y.; Chang C.S.; CHIH-HSIN YANG ; ANN-LII CHENG | British Journal of Cancer | 7 | 7 | |